ADXN
$0.79
Addex Therapeutics Ltd ADR
$.05
6.67%
ADXN
Earnings Whisper ®
N/A
3rd Quarter September 2022
Consensus:  ($0.56)
Revenue:  $0.43 Mil
Thursday
Nov 17
1:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ADXN reports earnings?
Beat
Meet
Miss

Where is ADXN's stock price going from here?
Up
Flat
Down
Stock chart of ADXN
Analysts
Summary of analysts' recommendations for ADXN
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Addex Therapeutics Ltd is a clinical-stage pharmaceutical company. It is focused on the development and commercialization of small molecule drugs for neurological disorders. The company's lead drug candidate includes dipraglurant, ADX71149 which are in clinical stage. Its Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 PAM for neurodegenerative disorders. GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Addex Therapeutics Ltd is based in Geneva, Switzerland.